Entity

Time filter

Source Type

CORVALVILLE, IA, United States

Patent
Integrated Dna Technologies, Inc. | Date: 2014-09-26

The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.


Patent
Integrated Dna Technologies, Inc. | Date: 2014-12-20

A composition comprising an oligonucleotide having the structure 5-Y R


Patent
Integrated Dna Technologies, Inc. | Date: 2014-11-07

The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3 end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.


Patent
City Of Hope and Integrated Dna Technologies, Inc. | Date: 2014-11-10

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (dsRNA), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.


Patent
Integrated Dna Technologies, Inc. | Date: 2014-03-14

A multi-well manifold assembly and method for reducing cross-contamination in continuous synthesis reactions in channels of microfluidic devices, for example oligonucleotide synthesis.

Discover hidden collaborations